Cagrilintide, with six amino acid substitutions in human amylin and a dual carboxylic fatty acid chain similar to semaglutide attached to the first amino acid, lysine, exhibits an extended half-life, allowing for a once-weekly subcutaneous administration regimen [97,98]
It decreases the overall quality of life, increases healthcare costs, and carries an increased risk of suicide
Under 200 M, we assume that compound 102 reduces ROS production mainly through GPX4
This dual action enhances insulin release and significantly reduces appetite, potentially making it more effective for managing body mass compared to Semaglutide, which primarily activates GLP-1 receptors
To date, evidence for an association between GLP-1RA and SIS is limited to a few preliminary reports from pharmacovigilance systems and pharmacoepidemiological studies
European Journal of Cancer Prevention , 33 (3), 208216